Observational studyAmerican journal of respiratory and critical care medicine2021
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Abstract readObservational Study
In one paragraph
Observational study in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 2 pooled it
27.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 230 citations in OpenAlex.
- Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Pooled it
- Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial.Annals of the American Thoracic Society · 2026Trial
- Laboratory diagnostics in personalised medicine - 36th Symposium of the Croatian society of medical biochemistry and laboratory medicine.Biochemia medica · 2026Review
- Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research.American journal of respiratory and critical care medicine · 2026Review
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- SOLAR: a noninterventional study of outcomes over the long term of people with cystic fibrosis (CF) aged ≥6 years treated with elexacaftor/tezacaftor/ivacaftor using data from the French CF Registry.ERJ open research · 2026Article
- Pregnancy-related effect on elexacaftor, tezacaftor and ivacaftor pharmacokinetics in women with cystic fibrosis.British journal of clinical pharmacology · 2026Observational
- CFTR modulators exert subset-specific phenotype remodeling on circulating neutrophils in cystic fibrosis.ImmunoHorizons · 2026Article
- Feasibility and Tolerance of High-Intensity Interval Training in Adults With Cystic Fibrosis.Archives of rehabilitation research and clinical translation · 2026Article
- Article
- Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis.Pediatric pulmonology · 2026Article
- TRIPS flexibilities help change policy and practice to increase access to medicines: evidence from 2001 to 2024.BMJ global health · 2026Article
- Effectiveness of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis carrying non-F508del variants in Brazil.Respiratory research & clinical practice · 2026Article
- The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy.Annals of the American Thoracic Society · 2026Review
- Advances in cystic fibrosis: CFTR modulator triple combinations.The European respiratory journal · 2026Article
- Clinical benefit without sweat chloride response after ETI therapy in an adult with cystic fibrosis bearing the L467F;F508del complexFrontiers in medicine · 2026Article
- People with cystic fibrosis with high sputum neutrophil elastase on elexacaftor-tezacaftor-ivacaftor exhibit worse pulmonary function and pro-inflammatory airway milieu.Scientific reports · 2025Article
- Transforming Care Models in Cystic Fibrosis: A Review.Healthcare (Basel, Switzerland) · 2025Review
- Real-World Safety and Effectiveness of Elexacaftor, Tezacaftor, and Ivacaftor in People with Cystic Fibrosis and Advanced Lung Disease: A Two-Year Multicenter Cohort Study.International journal of molecular sciences · 2025Observational
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byReply to Kuek2021
- Commented on by
Authors and funding
18 authors at 12 institutions in 3 countries.
Pierre-Régis BurgelUniversité de Paris, Institut Cochin, Unité 1016, Institut National de la Santé et de la Recherche Médicale, Paris, France.ORCID 0000-0003-0903-9828
Isabelle DurieuCystic Fibrosis Network, European Reference Network on Rare Respiratory Diseases, Frankfurt, Germany.
Raphaël ChironCentre de Mucoviscidose, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.
Sophie RamelCentre de Ressources et de Compétences de la Mucoviscidose, Fondation Ildys, Roscoff, France.
Isabelle Danner-BoucherService de Pneumologie, L'Institut Du Thorax, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Anne PrevotatCentre de Mucoviscidose, Service de Pneumologie et Immuno-allergologie, Hôpital Calmette, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.
Dominique GrenetService de Pneumologie, Hôpital Foch, Suresnes, France.
Christophe MarguetCentre des Maladies Respiratoires Pédiatriques et de la Mucoviscidose, Hospitalier Universitaire de Rouen Normandie, Université de Rouen Normandie, Équipe d'Accueil 2656, Institut National de la Santé et de la Recherche Médicale, Rouen, France.
Martine Reynaud-GaubertDepartment of Respiratory Medicine and Lung Transplantation, Nord Hospital, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France.
Julie MaceyRespiratory Medicine and Cystic Fibrosis Center, University Hospital Center of Bordeaux, Bordeaux, France.
Laurent MelyCystic Fibrosis Center, Renée Sabran Hospital, Giens, France.
Annlyse FantonCystic Fibrosis Resource and Competence Center for Adults, Department of Pulmonary Medicine, Dijon University Hospital, France.
Sébastien QuetantService Hospitalo-Universitaire de Pneumologie et Physiologie, Pôle Thorax et Vaisseaux, Centre Hospitalier Universitaire de Grenoble-Alpes, La Tronche, France.
Lydie LemonnierAssociation Vaincre la Mucoviscidose, Paris, France.
Jean-Louis PaillasseurEffi-Stat, Paris, France; and.
Jennifer Da SilvaUniversité de Paris, Institut Cochin, Unité 1016, Institut National de la Santé et de la Recherche Médicale, Paris, France.
Clémence MartinUniversité de Paris, Institut Cochin, Unité 1016, Institut National de la Santé et de la Recherche Médicale, Paris, France.
French Cystic Fibrosis Reference Network Study Group
Université Paris Cité · FRAix-Marseille Université · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire de Nantes · FRCystic Fibrosis Research Foundation · ITHôpital Foch · FRHôpital Renée Sabran · FRInserm · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Lille · FRVaincre la Mucoviscidose · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug CombinationsAdolescentAdultAgedAged, 80 and overAminophenolsChloride Channel AgonistsCystic FibrosisFemaleFranceHumansIndolesLung DiseasesMaleMembrane PotentialsMiddle AgedAminophenolsChloride Channel AgonistsDrug CombinationsIndolesPyrazolesPyridinesQuinolinescystic fibrosis transmembrane conductance regulator modulatorselexacaftorlung transplantation
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.